This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Stewart Wolf, M.D.; George M. Lewis, M.D.

J Am Med Assoc. 1941;116(18):2017-2018.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

An encouraging report of the treatment of pemphigus vulgaris was recently made by Topping and Knoefel.¹ They administered to their patient orally a flavin concentrate containing 970 Sherman-Bourquin units, or approximately 2.5 mg. of riboflavin daily. This patient had previously been treated by them with neoarsphenamine and sulfanilamide without success. After the administration of riboflavin had been started, however, the lesions cleared up and the patient remained well for several weeks. Later, after treatment was discontinued, the patient suffered a recurrence.² When the drug was resumed, this time in the dose of 5 mg. daily, the lesions cleared up again, and the patient has been apparently well since, nearly fourteen months after the institution of riboflavin therapy.²

On the strength of this favorable report, and since pemphigus is still considered a fatal disease, a patient in the New York Hospital suffering from pemphigus was treated for eleven . . . [Full Text PDF of this Article]

Author Affiliations
New York

From the New York Hospital and the Department of Medicine (Dermatology). Cornell University Medical College.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?